image by: HWN

HWN Suggests

Eli Lilly’s Weight-Loss Pill Sheds Pounds Fast—But Hits a Plateau: What New Trial Results Mean for the Obesity Drug Race

The appeal of a pill form is enormous. Weight-loss jabs have been game-changers, but a daily tablet is seen as a next-gen solution because it would be easier and more convenient for patients and healthcare systems alike. No needles, syringes, or special refrigeration required – just a swallow of a pill. Tablets are also expected to be cheaper to produce and distribute. “Pill versions are seen as a holy grail because they are easier to store, distribute and administer and are also expected to be cheaper,” The Guardian noted in its coverage. In short, an effective pill could make advanced obesity treatment far more accessible to millions who need it.

read full article

Articles of Interest

FDA Approves New Oral Weight Loss Pill Foundayo — Here’s What To Know

How Foundayo Differs From Oral Wegovy... Although both oral pills for obesity activate the GLP-1 pathway, they differ in structure and composition. The Wegovy pill is a modified protein that requires special absorption conditions in order to be effective and avoid the acidic environment in the stomach. For this reason, it must be taken on an empty stomach, so patients must fast 30 minutes after taking the drug. Foundayo, on the other hand, is a small molecule that is stable in the stomach and can be taken anytime of the day, with or without food. This makes Foundayo easier for patients to adhere to and offers a more convenient method to treat obesity.

Hate needles? Lilly’s weight-loss pill could get FDA approval next year, CEO says

The experimental pill for chronic weight management is called orforglipron—Ricks joked that even he had to practice pronouncing it—and designed to be taken once a day. By comparison, Zepbound is injected once a week. And whereas Zepbound is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist medication, orforglipron is classified as a nonpeptide GLP-1 receptor agonist drug.

Lilly’s GLP-1 pill outperforms Novo’s oral treatment in diabetes study

An investigational GLP-1 pill from Eli Lilly helped diabetes patients lower their blood sugar and weight more than an oral version of Ozempic sold by Novo Nordisk, results that support the efficacy of Lilly’s medicine as the company prepares to submit it to regulators. In a yearlong Phase 3 trial, the highest dose of Lily’s pill, orforglipron, lowered a measure of blood sugar called A1C by 1.9 percentage points, while the highest dose of Novo’s drug, marketed as Rybelsus, lowered A1C by 1.5 percentage points, when analyzing all patients regardless of discontinuations. The highest doses of Lilly’s and Novo’s pills also led to 8.2% and 5.3% weight loss, respectively.

Lilly’s new obesity pill linked to ‘serious’ safety signals, FDA requests more data

Eli Lilly’s newly approved oral obesity drug Foundayo has already run into a speedbump after the FDA detected safety risks affecting the heart and liver—signals that the regulator found serious enough to necessitate a postmarketing clinical trial.

Martha Stewart Is Hawking A GLP-1 That She ‘Does Not Take’ — And It's Igniting A Big Debate

“How the hell can you be a spokesperson for a GLP-1 when you don’t even take it??” a viewer on Reddit commented in response to the clip. “Why would I trust you at all when it’s obvious you’re only doing it for the money? Have these companies and celebrities lost their damn minds?”

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes

Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management. Additional data on the efficacy and safety of orforglipron are needed.